KDR and thyroid gland carcinoma: Also, VEGFR-2 inhibition will potentiate the anticancer activity of EGFR inhibitors.21 Based on the above, the dual inhibition of EGFR and VEGFR-2 represents a very promising protocol for cancer treatment.22 One of the most potent dual EGFR/VEGFR-2 inhibitors is vandetanib (Fig. 1) which is an FDA-approved drug against thyroid cancer.23